App-Quantinova.ai

EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT

P. J. Mease - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

EARLY DAMAGE AS MEASURED BY THE DAMAGE INDEX FOR ANTIPHOSPHOLIPID SYNDROME (DIAPS) IS NOT A PREDICTOR OF MORTALITY IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME

P. Gaspar - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

N/A

EDUCATIONAL NEEDS AMONG HEALTH PROFESSIONALS IN RHEUMATOLOGY: LOW AWARENESS OF EULAR OFFERINGS AND UNFAMILIARITY WITH COURSE CONTENT AS A MAJOR BARRIER – A EULAR FUNDED EUROPEAN SURVEY

L. Sperl - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Posterior Reversible Encephalopathy Syndrome

N/A

EFFECT OF ATACICEPT ON RENAL FUNCTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

D. Isenberg - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

EFFECT OF AVACOPAN ON RELAPSE RATES AND RELAPSE-FREE TIME IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS, RESULTS OF THE PHASE 3 ADVOCATE STUDY

P. A. Merkel - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Prednisone

EFFECT OF EARLY ETANERCEPT TREATMENT ON CIRCULATING LIPOPROTEINS DIFFERS TO TREATMENT WITH METHOTREXATE AND IS MODULATED BY CLINICAL DISEASE ACTIVITY

R. Shukla - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Methotrexate

EFFECT OF FOOT ORTHOSES IN REDUCING PAIN IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A 12-MONTH RANDOMISED CLINICAL TRIAL

A. Fellas - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

EFFECT OF GUSELKUMAB ON SERUM BIOMARKERS IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE COSMOS STUDY

G. Schett - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

guselkumab (IV)

EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS

P. J. Mease - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Sacroiliitis

guselkumab (IV)

EFFECT OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) AND RISK FACTORS FOR RAPID DECLINE IN FORCED VITAL CAPACITY: FURTHER ANALYSES OF THE SENSCIS TRIAL

D. Khanna - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Interstitial lung disease

Nintedanib

EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACROILIAC JOINTS AND SPINE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 2-YEAR IMAGING OUTCOMES FROM A PHASE III RANDOMISED TRIAL

J. Braun - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Non-radiographic axial spondyloarthritis

secukinumab

EFFECTIVENESS OF NON-PHARMACOLOGICAL INTERVENTIONS TO PROMOTE WORK PARTICIPATION IN PEOPLE WITH RMDs: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Butink - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Spondylometaphyseal dysplasia, sedaghatian type

N/A

EFFECTIVENESS OF REMOTE CARE INTERVENTIONS: A SYSTEMATIC REVIEW INFORMING THE 2022 EULAR POINTS TO CONSIDER FOR REMOTE CARE IN RHEUMATIC AND MUSCULOSKELETAL DISEASES

A. Marques - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD)

S. Assassi - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Interstitial lung disease

Nintedanib

EFFECTS OF TREATMENT WITH RISANKIZUMAB ON MINIMAL DISEASE ACTIVITY (MDA) AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (DAPSA): AN ANALYSIS OF THE KEEPsAKE-1 AND -2 TRIALS

J. F. Merola - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Psoriatic arthritis

Risankizumab

EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL

S. Ramiro - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

Adalimumab

EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM TWO RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDIES

E. F. Morand - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Glucocorticoid

EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (sJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS

F. De Benedetti - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Macrophage activation syndrome

Interferon Gamma

EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY

D. Aletaha - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Filgotinib

EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE, WITH 4 OR <4 POOR PROGNOSTIC FACTORS: A POST HOC ANALYSIS OF THE FINCH 1 STUDY

B. Combe - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Methotrexate

Filters

45280 Abstracts